HemaSphere (Aug 2023)
S166: KER-050 TREATMENT IMPROVED MARKERS OF ERYTHROPOIETIC ACTIVITY AND HEMATOPOIESIS OVER SIX MONTHS WHICH RESULTED IN HEMATOLOGICAL RESPONSES ACROSS A BROAD, LOWER-RISK MDS POPULATION
- Aristoteles Giagounidis,
- Thomas Cluzeau,
- María Díez Campelo,
- David Ross,
- Lynette Chee,
- Shuhying Tan,
- Christine Graham,
- Wei Feng,
- Ming Yang,
- Ying Jiang,
- Miranda Ross,
- Allie Mcginty,
- Suresh Bobba,
- Christopher Rovaldi,
- Simon Cooper,
- Jen Salstrom
Affiliations
- Aristoteles Giagounidis
- 1 Marien Hospital
- Thomas Cluzeau
- 2 Nice University Hospital
- María Díez Campelo
- 3 Hospital Universitario de Salamanca, Nice, France
- David Ross
- 4 Flinders Medical Centre, Adelaide, Australia
- Lynette Chee
- 5 The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne
- Shuhying Tan
- 6 St. Vincent’s Hospital, Melbourne, Australia
- Christine Graham
- 7 Keros Therapeutics, Lexington, United States
- Wei Feng
- 7 Keros Therapeutics, Lexington, United States
- Ming Yang
- 7 Keros Therapeutics, Lexington, United States
- Ying Jiang
- 7 Keros Therapeutics, Lexington, United States
- Miranda Ross
- 7 Keros Therapeutics, Lexington, United States
- Allie Mcginty
- 7 Keros Therapeutics, Lexington, United States
- Suresh Bobba
- 7 Keros Therapeutics, Lexington, United States
- Christopher Rovaldi
- 7 Keros Therapeutics, Lexington, United States
- Simon Cooper
- 7 Keros Therapeutics, Lexington, United States
- Jen Salstrom
- 7 Keros Therapeutics, Lexington, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000967576.33522.1a
- Journal volume & issue
-
Vol. 7
p. e335221a
Abstract
No abstracts available.
